昊海生科(688366)
 
 
  日线
顶尖财经网欢迎您!
  K线
 
 最新动态
  投资评级

研究机构 评级日期 最新评级 上次评级
财通证券 2024-01-30 增持
开源证券 2024-01-07 买入
中信证券 2023-12-04 增持
东方财富证券 2023-11-27 增持
  盈利预测
据昊海生科三季报分析:

  盈利能力有所加强,总资产收益能力大幅提升

  成长能力明显改善,企业成长潜力得到恢复

  偿债能力维持稳定,偿还流动负债能力很强

  运营能力有所加强,流动资产合理利用率有所优化

  现金流能力有所加强,公司资金利用效率获明显提升

  财务数据
    截至第三季度实现净利润3.27亿元,每股收益1.91元。

    截至第三季度最新股东权益607835.80万元,未分配利润263750.78万元。

    截至第三季度最新总资产708942.65万元,负债101106.86万元。

利润表
报告期2023-09-302023-06-302023-03-312022-12-31
营业总收入1,981,789,458.111,312,902,451.62611,252,893.652,130,275,956.41
营业总成本1,616,376,970.691,075,921,430.82508,741,359.431,864,419,959.11
营业利润388,603,227.42248,632,839.83111,265,909.95234,586,278.61
利润总额389,349,352.39249,797,428.33112,095,668.59235,726,502.74
净利润326,967,441.02208,687,100.0684,951,683.69190,331,727.62
其他综合收益-2,992,987.8740,876,316.383,063,929.44-89,629,096.3
综合收益总额323,974,453.15249,563,416.4488,015,613.13100,702,631.32
资产负债表
报告期2023-09-302023-06-302023-03-312022-12-31
流动资产合计3,715,795,672.923,878,569,755.923,660,348,521.723,532,115,166.92
非流动资产合计3,373,630,857.823,375,598,403.313,323,687,623.673,360,283,086.96
资产总计7,089,426,530.747,254,168,159.236,984,036,145.396,892,398,253.88
流动负债合计580,055,876.42657,787,506.67523,418,974.28511,273,736.22
非流动负债合计431,012,686.44505,809,020.53563,623,031.64478,740,001.76
负债合计1,011,068,562.861,163,596,527.21,087,042,005.92990,013,737.98
归属于母公司股东权益合计5,704,966,947.125,709,617,329.585,514,492,058.385,514,610,290.63
股东权益合计6,078,357,967.886,090,571,632.035,896,994,139.475,902,384,515.9
负债和股东权益合计7,089,426,530.747,254,168,159.236,984,036,145.396,892,398,253.88
现金流量表
报告期2023-09-302023-06-302023-03-312022-12-31
经营活动现金流入小计2,202,212,262.841,467,437,782.25651,744,340.232,313,065,400.02
经营活动现金流出小计1,810,647,919.361,183,466,418.03571,813,377.742,081,769,369.12
经营活动产生的现金流量净额391,564,343.48283,971,364.2279,930,962.49231,296,030.9
投资活动现金流入小计1,089,423,627.13718,981,754.53335,310,779.41,623,674,345.56
投资活动现金流出小计1,487,246,691.67974,622,221.68179,126,769.442,305,489,242.18
投资活动产生的现金流量净额-397,823,064.54-255,640,467.15156,184,009.96-681,814,896.62
筹资活动现金流入小计329,686,285.31235,163,480.78139,254,797.5966,703,633.58
筹资活动现金流出小计487,575,027.29187,541,423.1160,190,501.57355,053,185.17
筹资活动产生的现金流量净额-157,888,741.9847,622,057.68-20,935,703.98-288,349,551.59
汇率变动对现金及现金等价物的影响11,313,076.0216,514,567.72-2,155,537.7514,172,941
现金及现金等价物净增加额-152,834,387.0292,467,522.47213,023,730.72-724,695,476.31
期末现金及现金等价物余额406,363,089.01651,664,998.5772,221,206.75559,197,476.03
  主营收入+营业利润
 
  净利润+每股收益
  股东权益+未分配利润
 
  总资产+负债
  投资要点

    截至第三季度实现净利润3.27亿元,每股收益1.91元。

    截至第三季度最新股东权益607835.80万元,未分配利润263750.78万元。

    截至第三季度最新总资产708942.65万元,负债101106.86万元。

利润表
报告期2023-09-302023-06-302023-03-312022-12-31
营业总收入1,981,789,458.111,312,902,451.62611,252,893.652,130,275,956.41
营业总成本1,616,376,970.691,075,921,430.82508,741,359.431,864,419,959.11
营业利润388,603,227.42248,632,839.83111,265,909.95234,586,278.61
利润总额389,349,352.39249,797,428.33112,095,668.59235,726,502.74
净利润326,967,441.02208,687,100.0684,951,683.69190,331,727.62
其他综合收益-2,992,987.8740,876,316.383,063,929.44-89,629,096.3
综合收益总额323,974,453.15249,563,416.4488,015,613.13100,702,631.32
资产负债表
报告期2023-09-302023-06-302023-03-312022-12-31
流动资产合计3,715,795,672.923,878,569,755.923,660,348,521.723,532,115,166.92
非流动资产合计3,373,630,857.823,375,598,403.313,323,687,623.673,360,283,086.96
资产总计7,089,426,530.747,254,168,159.236,984,036,145.396,892,398,253.88
流动负债合计580,055,876.42657,787,506.67523,418,974.28511,273,736.22
非流动负债合计431,012,686.44505,809,020.53563,623,031.64478,740,001.76
负债合计1,011,068,562.861,163,596,527.21,087,042,005.92990,013,737.98
归属于母公司股东权益合计5,704,966,947.125,709,617,329.585,514,492,058.385,514,610,290.63
股东权益合计6,078,357,967.886,090,571,632.035,896,994,139.475,902,384,515.9
负债和股东权益合计7,089,426,530.747,254,168,159.236,984,036,145.396,892,398,253.88
现金流量表
报告期2023-09-302023-06-302023-03-312022-12-31
经营活动现金流入小计2,202,212,262.841,467,437,782.25651,744,340.232,313,065,400.02
经营活动现金流出小计1,810,647,919.361,183,466,418.03571,813,377.742,081,769,369.12
经营活动产生的现金流量净额391,564,343.48283,971,364.2279,930,962.49231,296,030.9
投资活动现金流入小计1,089,423,627.13718,981,754.53335,310,779.41,623,674,345.56
投资活动现金流出小计1,487,246,691.67974,622,221.68179,126,769.442,305,489,242.18
投资活动产生的现金流量净额-397,823,064.54-255,640,467.15156,184,009.96-681,814,896.62
筹资活动现金流入小计329,686,285.31235,163,480.78139,254,797.5966,703,633.58
筹资活动现金流出小计487,575,027.29187,541,423.1160,190,501.57355,053,185.17
筹资活动产生的现金流量净额-157,888,741.9847,622,057.68-20,935,703.98-288,349,551.59
汇率变动对现金及现金等价物的影响11,313,076.0216,514,567.72-2,155,537.7514,172,941
现金及现金等价物净增加额-152,834,387.0292,467,522.47213,023,730.72-724,695,476.31
期末现金及现金等价物余额406,363,089.01651,664,998.5772,221,206.75559,197,476.03
  十大流通股东
十大流通股东 报告期:2023-09-30
股东名称 持股数量(万股) 占总股本比例(%) 上期持股变化(万股)
蒋伟4444.9025.940.00
香港中央结算(代理人)有限公司3281.9919.16-0.14
游捷2880.0016.810.00
楼国梁615.123.590.00
吴剑英603.403.520.00
侯永泰600.633.510.00
上海湛泽企业管理合伙企业(有限合伙)474.102.77-173.00
彭锦华283.001.65283.00
中国工商银行股份有限公司-中欧医疗健康混合型证券投资基金201.151.17201.15
刘远中200.001.170.00
  主力控盘
  公司简介
昊海生科 所属地域: 上海市 涉及概念: 年报预增,沪股通,医美概念,眼科医疗,融资融券
主营业务: 基因工程、化学合成、天然药物、诊断试剂内的技术开发、技术转让、技术咨询、技术服务;小容量注射剂、原料药、生物工程产品、Ⅲ类6822植入体内或长期接触体内的眼科光学器具、6864可吸收性止血、防粘连材料的研究、生产;从事货物及技术的进出口业务,医疗器械的经营,乙醇(无水)的批发(租用存储设施),化工原料及产品(除危险化学品)、化妆品的销售。
上市日期: 2019-10-30 每股净资产: 33.30元 每股收益: 1.91元 净利润: 3.27亿元 净利润增长率: 102.04%
营业收入: 19.82亿元 每股现金流: 2.29元 每股公积金: 17.28元 每股未分配利润: 15.39元 总股本: 1.71亿 流通股: 1.39亿
以上信息为合作方、加盟公司及会员收集,本站不拥有版权,版权归原作者所有,所载文章、数据仅供参考,据此操作,风险自负。

中 华 顶 尖 财 经 -- 中 华 顶 尖 网 络 信 息 服 务 中 心